Dialysis reduces portal pressure in patients with chronic hepatitis C

Sandeep Khurana, Thomas Simcox, William Twaddell, Cinthia Drachenberg, Mark Flasar

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The purpose of this study was to characterize changes in hepatic venous pressures in patients with chronic hepatitis C. The histology and laboratory data from patients with chronic hepatitis C who underwent a transjugular liver biopsy (TJLB) and hepatic venous pressure gradient measurement were analyzed. Portal hypertension was defined as hepatic venous pressure gradient ≥6 mm Hg. A single pathologist masked to hepatic venous pressure gradient scored liver sections for inflammation and fibrosis. The patients with high-grade inflammation (relative risk [RR] 2.82, P = 0.027, multivariate analysis) and late-stage fibrosis (RR 2.81, P = 0.022) were more likely to have a hepatic venous pressure gradient ≥6 mm Hg, while the patients on dialysis (RR 0.32, P = 0.01) were less likely to have a hepatic venous pressure gradient ≥6 mm Hg. The patients on dialysis (n = 58) had an elevated serum blood urea nitrogen and creatinine when compared with those who were not (n = 75) (47.6 ± 3.3 and 7.98 ± 0.4 vs. 25.9 ± 2.0 and 1.66 ± 0.22 mg/dL, respectively; P < 0.001). While the hepatic venous pressure gradient increased with the rising levels of liver fibrosis in the latter group (P < 0.01), it did not change in the patients on dialysis (P = 0.41). The median hepatic venous pressure gradient was especially low in late-stage fibrosis patients on dialysis when compared with the latter group (5 vs. 10 mm Hg, P = 0.017). In patients on dialysis, serum transaminases were low across all levels of fibrosis. Twenty-three of the 92 patients with early fibrosis had a hepatic venous pressure gradient ≥6 mm Hg. In patients with chronic hepatitis C, concomitant TJLB and hepatic venous pressure gradient measurement identify those who have early fibrosis and portal hypertension. Long-term hemodialysis may reduce portal pressure in these patients.

Original languageEnglish (US)
Pages (from-to)570-579
Number of pages10
JournalArtificial Organs
Volume34
Issue number7
DOIs
StatePublished - Jan 1 2010

Fingerprint

Portal Pressure
Dialysis
Chronic Hepatitis C
Pressure gradient
Venous Pressure
Liver
Fibrosis
Biopsy
Portal Hypertension
Histology
Transaminases
Urea
Inflammation
Creatinine
Blood
Nitrogen
Blood Urea Nitrogen
Serum
Liver Cirrhosis
Renal Dialysis

Keywords

  • Dialysis
  • Hepatic venous pressure gradient
  • Hepatitis C
  • Portal hypertension
  • Renal failure

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Bioengineering
  • Medicine (miscellaneous)
  • Medicine(all)

Cite this

Khurana, S., Simcox, T., Twaddell, W., Drachenberg, C., & Flasar, M. (2010). Dialysis reduces portal pressure in patients with chronic hepatitis C. Artificial Organs, 34(7), 570-579. https://doi.org/10.1111/j.1525-1594.2009.00925.x

Dialysis reduces portal pressure in patients with chronic hepatitis C. / Khurana, Sandeep; Simcox, Thomas; Twaddell, William; Drachenberg, Cinthia; Flasar, Mark.

In: Artificial Organs, Vol. 34, No. 7, 01.01.2010, p. 570-579.

Research output: Contribution to journalArticle

Khurana, S, Simcox, T, Twaddell, W, Drachenberg, C & Flasar, M 2010, 'Dialysis reduces portal pressure in patients with chronic hepatitis C', Artificial Organs, vol. 34, no. 7, pp. 570-579. https://doi.org/10.1111/j.1525-1594.2009.00925.x
Khurana, Sandeep ; Simcox, Thomas ; Twaddell, William ; Drachenberg, Cinthia ; Flasar, Mark. / Dialysis reduces portal pressure in patients with chronic hepatitis C. In: Artificial Organs. 2010 ; Vol. 34, No. 7. pp. 570-579.
@article{08c667fb4f7e481b85b8846151beb7e7,
title = "Dialysis reduces portal pressure in patients with chronic hepatitis C",
abstract = "The purpose of this study was to characterize changes in hepatic venous pressures in patients with chronic hepatitis C. The histology and laboratory data from patients with chronic hepatitis C who underwent a transjugular liver biopsy (TJLB) and hepatic venous pressure gradient measurement were analyzed. Portal hypertension was defined as hepatic venous pressure gradient ≥6 mm Hg. A single pathologist masked to hepatic venous pressure gradient scored liver sections for inflammation and fibrosis. The patients with high-grade inflammation (relative risk [RR] 2.82, P = 0.027, multivariate analysis) and late-stage fibrosis (RR 2.81, P = 0.022) were more likely to have a hepatic venous pressure gradient ≥6 mm Hg, while the patients on dialysis (RR 0.32, P = 0.01) were less likely to have a hepatic venous pressure gradient ≥6 mm Hg. The patients on dialysis (n = 58) had an elevated serum blood urea nitrogen and creatinine when compared with those who were not (n = 75) (47.6 ± 3.3 and 7.98 ± 0.4 vs. 25.9 ± 2.0 and 1.66 ± 0.22 mg/dL, respectively; P < 0.001). While the hepatic venous pressure gradient increased with the rising levels of liver fibrosis in the latter group (P < 0.01), it did not change in the patients on dialysis (P = 0.41). The median hepatic venous pressure gradient was especially low in late-stage fibrosis patients on dialysis when compared with the latter group (5 vs. 10 mm Hg, P = 0.017). In patients on dialysis, serum transaminases were low across all levels of fibrosis. Twenty-three of the 92 patients with early fibrosis had a hepatic venous pressure gradient ≥6 mm Hg. In patients with chronic hepatitis C, concomitant TJLB and hepatic venous pressure gradient measurement identify those who have early fibrosis and portal hypertension. Long-term hemodialysis may reduce portal pressure in these patients.",
keywords = "Dialysis, Hepatic venous pressure gradient, Hepatitis C, Portal hypertension, Renal failure",
author = "Sandeep Khurana and Thomas Simcox and William Twaddell and Cinthia Drachenberg and Mark Flasar",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1525-1594.2009.00925.x",
language = "English (US)",
volume = "34",
pages = "570--579",
journal = "Artificial Organs",
issn = "0160-564X",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Dialysis reduces portal pressure in patients with chronic hepatitis C

AU - Khurana, Sandeep

AU - Simcox, Thomas

AU - Twaddell, William

AU - Drachenberg, Cinthia

AU - Flasar, Mark

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The purpose of this study was to characterize changes in hepatic venous pressures in patients with chronic hepatitis C. The histology and laboratory data from patients with chronic hepatitis C who underwent a transjugular liver biopsy (TJLB) and hepatic venous pressure gradient measurement were analyzed. Portal hypertension was defined as hepatic venous pressure gradient ≥6 mm Hg. A single pathologist masked to hepatic venous pressure gradient scored liver sections for inflammation and fibrosis. The patients with high-grade inflammation (relative risk [RR] 2.82, P = 0.027, multivariate analysis) and late-stage fibrosis (RR 2.81, P = 0.022) were more likely to have a hepatic venous pressure gradient ≥6 mm Hg, while the patients on dialysis (RR 0.32, P = 0.01) were less likely to have a hepatic venous pressure gradient ≥6 mm Hg. The patients on dialysis (n = 58) had an elevated serum blood urea nitrogen and creatinine when compared with those who were not (n = 75) (47.6 ± 3.3 and 7.98 ± 0.4 vs. 25.9 ± 2.0 and 1.66 ± 0.22 mg/dL, respectively; P < 0.001). While the hepatic venous pressure gradient increased with the rising levels of liver fibrosis in the latter group (P < 0.01), it did not change in the patients on dialysis (P = 0.41). The median hepatic venous pressure gradient was especially low in late-stage fibrosis patients on dialysis when compared with the latter group (5 vs. 10 mm Hg, P = 0.017). In patients on dialysis, serum transaminases were low across all levels of fibrosis. Twenty-three of the 92 patients with early fibrosis had a hepatic venous pressure gradient ≥6 mm Hg. In patients with chronic hepatitis C, concomitant TJLB and hepatic venous pressure gradient measurement identify those who have early fibrosis and portal hypertension. Long-term hemodialysis may reduce portal pressure in these patients.

AB - The purpose of this study was to characterize changes in hepatic venous pressures in patients with chronic hepatitis C. The histology and laboratory data from patients with chronic hepatitis C who underwent a transjugular liver biopsy (TJLB) and hepatic venous pressure gradient measurement were analyzed. Portal hypertension was defined as hepatic venous pressure gradient ≥6 mm Hg. A single pathologist masked to hepatic venous pressure gradient scored liver sections for inflammation and fibrosis. The patients with high-grade inflammation (relative risk [RR] 2.82, P = 0.027, multivariate analysis) and late-stage fibrosis (RR 2.81, P = 0.022) were more likely to have a hepatic venous pressure gradient ≥6 mm Hg, while the patients on dialysis (RR 0.32, P = 0.01) were less likely to have a hepatic venous pressure gradient ≥6 mm Hg. The patients on dialysis (n = 58) had an elevated serum blood urea nitrogen and creatinine when compared with those who were not (n = 75) (47.6 ± 3.3 and 7.98 ± 0.4 vs. 25.9 ± 2.0 and 1.66 ± 0.22 mg/dL, respectively; P < 0.001). While the hepatic venous pressure gradient increased with the rising levels of liver fibrosis in the latter group (P < 0.01), it did not change in the patients on dialysis (P = 0.41). The median hepatic venous pressure gradient was especially low in late-stage fibrosis patients on dialysis when compared with the latter group (5 vs. 10 mm Hg, P = 0.017). In patients on dialysis, serum transaminases were low across all levels of fibrosis. Twenty-three of the 92 patients with early fibrosis had a hepatic venous pressure gradient ≥6 mm Hg. In patients with chronic hepatitis C, concomitant TJLB and hepatic venous pressure gradient measurement identify those who have early fibrosis and portal hypertension. Long-term hemodialysis may reduce portal pressure in these patients.

KW - Dialysis

KW - Hepatic venous pressure gradient

KW - Hepatitis C

KW - Portal hypertension

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=77954350439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954350439&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1594.2009.00925.x

DO - 10.1111/j.1525-1594.2009.00925.x

M3 - Article

C2 - 20653650

AN - SCOPUS:77954350439

VL - 34

SP - 570

EP - 579

JO - Artificial Organs

JF - Artificial Organs

SN - 0160-564X

IS - 7

ER -